NewEdge Advisors LLC Has $103.13 Million Stake in AbbVie Inc. $ABBV

NewEdge Advisors LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 8.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 555,573 shares of the company’s stock after acquiring an additional 45,537 shares during the quarter. AbbVie accounts for about 0.5% of NewEdge Advisors LLC’s investment portfolio, making the stock its 28th largest holding. NewEdge Advisors LLC’s holdings in AbbVie were worth $103,125,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its position in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Aigen Investment Management LP acquired a new stake in AbbVie in the 1st quarter valued at about $560,000. Maia Wealth LLC lifted its position in shares of AbbVie by 5.7% in the first quarter. Maia Wealth LLC now owns 3,046 shares of the company’s stock valued at $638,000 after buying an additional 163 shares during the last quarter. Finally, Sustainable Insight Capital Management LLC lifted its holdings in AbbVie by 30.8% during the 1st quarter. Sustainable Insight Capital Management LLC now owns 1,698 shares of the company’s stock valued at $356,000 after purchasing an additional 400 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABBV has been the subject of several research reports. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. JPMorgan Chase & Co. lifted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. BMO Capital Markets boosted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a report on Friday, September 12th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and increased their target price for the stock from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, Bank of America raised their target price on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $243.85.

AbbVie Stock Down 0.1%

NYSE ABBV opened at $222.83 on Wednesday. The business has a fifty day moving average price of $228.12 and a two-hundred day moving average price of $209.10. The stock has a market capitalization of $393.83 billion, a PE ratio of 168.81, a PEG ratio of 1.21 and a beta of 0.36. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 EPS. AbbVie’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.